Radiopharm Theranostics (NASDAQ:RADX) Price Target Lowered to $13.00 at B. Riley

Radiopharm Theranostics (NASDAQ:RADX) had its target price lowered by stock analysts at B. Riley from $15.00 to $13.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. B. Riley’s price target points to a potential upside of 173.68% from the company’s previous close.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $14.33.

Radiopharm Theranostics Price Performance

Shares of Radiopharm Theranostics stock traded up $0.08 during midday trading on Wednesday, hitting $4.75. 2,149 shares of the company were exchanged, compared to its average volume of 78,470. The firm has a 50 day simple moving average of $5.69 and a 200-day simple moving average of $5.19. Radiopharm Theranostics has a 52 week low of $3.50 and a 52 week high of $50.82.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. purchased a new position in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned about 0.10% of Radiopharm Theranostics as of its most recent SEC filing.

About Radiopharm Theranostics

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.